Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:1903311110 | Esophagus | ESCC | regulation of mRNA metabolic process | 210/8552 | 288/18723 | 3.25e-21 | 5.56e-19 | 210 |
GO:0050684110 | Esophagus | ESCC | regulation of mRNA processing | 109/8552 | 137/18723 | 3.51e-16 | 2.59e-14 | 109 |
GO:000635414 | Esophagus | ESCC | DNA-templated transcription, elongation | 76/8552 | 91/18723 | 8.35e-14 | 4.11e-12 | 76 |
GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
GO:190331316 | Esophagus | ESCC | positive regulation of mRNA metabolic process | 87/8552 | 118/18723 | 5.10e-10 | 1.32e-08 | 87 |
GO:0030099111 | Esophagus | ESCC | myeloid cell differentiation | 232/8552 | 381/18723 | 1.22e-09 | 2.90e-08 | 232 |
GO:000636814 | Esophagus | ESCC | transcription elongation from RNA polymerase II promoter | 56/8552 | 69/18723 | 1.40e-09 | 3.30e-08 | 56 |
GO:003278412 | Esophagus | ESCC | regulation of DNA-templated transcription, elongation | 45/8552 | 53/18723 | 3.64e-09 | 7.61e-08 | 45 |
GO:00065136 | Esophagus | ESCC | protein monoubiquitination | 53/8552 | 67/18723 | 2.11e-08 | 4.03e-07 | 53 |
GO:001657414 | Esophagus | ESCC | histone ubiquitination | 40/8552 | 47/18723 | 2.40e-08 | 4.55e-07 | 40 |
GO:009872714 | Esophagus | ESCC | maintenance of cell number | 90/8552 | 134/18723 | 3.94e-07 | 5.43e-06 | 90 |
GO:001982714 | Esophagus | ESCC | stem cell population maintenance | 88/8552 | 131/18723 | 5.23e-07 | 6.97e-06 | 88 |
GO:003424312 | Esophagus | ESCC | regulation of transcription elongation from RNA polymerase II promoter | 28/8552 | 32/18723 | 1.02e-06 | 1.29e-05 | 28 |
GO:003112412 | Esophagus | ESCC | mRNA 3'-end processing | 47/8552 | 62/18723 | 1.29e-06 | 1.58e-05 | 47 |
GO:003144013 | Esophagus | ESCC | regulation of mRNA 3'-end processing | 25/8552 | 28/18723 | 1.77e-06 | 2.10e-05 | 25 |
GO:003278613 | Esophagus | ESCC | positive regulation of DNA-templated transcription, elongation | 24/8552 | 27/18723 | 3.48e-06 | 3.84e-05 | 24 |
GO:00073698 | Esophagus | ESCC | gastrulation | 115/8552 | 185/18723 | 4.35e-06 | 4.64e-05 | 115 |
GO:00103904 | Esophagus | ESCC | histone monoubiquitination | 25/8552 | 29/18723 | 7.24e-06 | 7.20e-05 | 25 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LEO1 | SNV | Missense_Mutation | | c.1174N>A | p.Gln392Lys | p.Q392K | Q8WVC0 | protein_coding | tolerated(0.18) | benign(0.082) | TCGA-DD-A1EE-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
LEO1 | SNV | Missense_Mutation | novel | c.1565N>T | p.Pro522Leu | p.P522L | Q8WVC0 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-DD-AACI-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
LEO1 | SNV | Missense_Mutation | novel | c.599N>T | p.Glu200Val | p.E200V | Q8WVC0 | protein_coding | deleterious_low_confidence(0) | benign(0.27) | TCGA-DD-AADM-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
LEO1 | SNV | Missense_Mutation | | c.1249N>C | p.Glu417Gln | p.E417Q | Q8WVC0 | protein_coding | deleterious(0.01) | possibly_damaging(0.631) | TCGA-44-6144-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
LEO1 | SNV | Missense_Mutation | | c.592N>C | p.Asp198His | p.D198H | Q8WVC0 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-91-6848-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | cisplatin | CR |
LEO1 | SNV | Missense_Mutation | rs751561202 | c.1595N>A | p.Arg532His | p.R532H | Q8WVC0 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-34-2600-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LEO1 | SNV | Missense_Mutation | novel | c.740N>T | p.Asp247Val | p.D247V | Q8WVC0 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.617) | TCGA-37-4130-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
LEO1 | SNV | Missense_Mutation | novel | c.1406N>T | p.Asn469Ile | p.N469I | Q8WVC0 | protein_coding | deleterious(0.01) | benign(0.037) | TCGA-UF-A7J9-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LEO1 | SNV | Missense_Mutation | novel | c.1268N>T | p.Arg423Met | p.R423M | Q8WVC0 | protein_coding | deleterious(0) | benign(0.387) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
LEO1 | SNV | Missense_Mutation | rs767042967 | c.862N>T | p.Arg288Cys | p.R288C | Q8WVC0 | protein_coding | deleterious(0.01) | possibly_damaging(0.543) | TCGA-BR-8361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |